CytRx arimoclomol clinical hold
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CytRx hopes to begin a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol by the end of 2005 based on communications from FDA regarding the agency's clinical hold on the trial, the Los Angeles firm says Aug. 10. FDA cited two actions required to lift the hold: submission of existing clinical information on CytRx' related small molecule agent bimoclomol, "which has been more extensively tested for safety in humans than arimoclomol"; and a protocol amendment to the study "to add specific clinical tests to be administered to patients enrolled in the study." CytRx announced the hold July 21...
You may also be interested in...
CytRx arimoclomol begins Phase II
CytRx is initiating a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol, the firm says Sept. 22. CytRx received notification from FDA Sept. 21 regarding a clinical hold on the development program for the molecular chaperone activator announced last July (1Pharmaceutical Approvals Monthly August 2005, In Brief). The double-blind, placebo-controlled trial will enroll 80 patients from eight to ten U.S. centers. Primary endpoints are safety and tolerability; secondary endpoints include the revised ALS Functional Rating Scale. A second Phase II trial in 300 patients is slated to begin "soon after completion" of the present trial. CytRx announced FDA's decision to grant arimoclomol fast-track status Sept. 26...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.